Skip to main content

Tango Therapeutics, Inc 8-K, filed Nov 9, 2026

Tango Therapeutics, Inc. (TNGX)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Tango Therapeutics, Inc filed this 8-K on November 9, 2026.

Tango Therapeutics reported 82% ORR and 88% PFS for vopimetostat plus daraxonrasib in pancreatic cancer, plans Phase 3 in first half of 2027, and held $977.5 million in cash, cash equivalents and marketable securities at September 30, 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits